AustraliaHealth

Neurizon Therapeutics (ASX:NUZ) secures ethics approval for a Phase 1 study of its NUZ-001 oral liquid formulation.

Firebrick Pharma (ASX:FRE) has achieved a regulatory milestone in North America with the Canadian Intellectual Property Office.

Nexsen (ASX:NXN) has achieved a milestone in its international expansion, announcing a binding term sheet with GHK Hospital.

Cancer diagnostics firm Pacific Edge (ASX:PEB) has capitalised on investor appetite, announcing an upsized NZ$25.4 million equity placement.

Healius (ASX:HLS) narrowed its EBITDA guidance to $259M–$264M and launched a strategic asset review for FY26.

Biome Australia (ASX:BIO) executed a two-year extension to its exclusive supply agreement with Probiotical.

Bioxyne (ASX:BXN) announced a major $50 million exclusive supply agreement with German pharmaceutical giant ADREXpharma.

EMVision Medical Devices (ASX:EMV) announced an expansion of its pivotal FDA De Novo trial.

BCAL Diagnostics (ASX:BDX), an Australian healthcare innovator specialising in early-stage cancer detection, appointed Anne-Louise Arnett as its CEO.

Biotech giant CSL (ASX:CSL) issued an update to its 2026 financial year outlook, softening revenue and profit expectations.

Amplia Therapeutics (ASX:ATX) has partnered with the Australia New Zealand Gynaecological Oncology Group to launch a new clinical trial targeting ovarian cancer.

Ramsay Santé booked a 3.1% revenue rise to €4bn in its 9M results, driven by strong Nordic performance and French demand.